2026-01-22 - Analysis Report
**UnitedHealth Group (UNH) Analysis Report**

### Company Overview
UnitedHealth Group is a global health company that provides health, well-being, and investment management solutions to help people live healthier lives and more sustainable communities.

### Return Rate Comparison
- **Review Stock (UNH):** Cumulative return of -17.56%
- **Comparison Stock (S&P 500, VOO):** Cumulative return of 91.55%
- **Degree of Divergence:** -114.80 (relative divergence: 6.30%)

### Alpha, Beta Analysis
| Year  | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------|------|------|-------|------|-------|
| 2016-2018 | 22.0% | 18.6% | 18.0% | 0.9 | 225.7B |
| 2017-2019 | 27.0% | 18.6% | 10.0% | 0.9 | 266.3B |
| 2018-2020 | -41.0% | 32.5% | -62.0% | 1.1 | 317.7B |
| 2019-2021 | 16.0% | 32.5% | -27.0% | 1.1 | 454.9B |
| 2020-2022 | 0.0% | 31.5% | 2.0% | 0.9 | 480.3B |
| 2021-2023 | 23.0% | 13.4% | 23.0% | 0.5 | 476.9B |
| 2022-2024 | -24.0% | 23.1% | -44.0% | 0.4 | 458.2B |
| 2023-2025 | -55.0% | 58.5% | -118.0% | 0.3 | 299.0B |

### Recent Stock Price Fluctuations
- **Close:** $347.75
- **Last-Market Change:** 2.75 (up)
- **5-day SMA:** $338.22
- **20-day SMA:** $336.30
- **60-day SMA:** $333.21

### RSI, PPO Analysis
- **Market Risk Indicator (MRI):** 0.80 (Medium Investment)
- **RSI:** 60.26
- **PPO:** 0.07
- **Hybrid Signal:** Buy (Cash 0%)
- **Risk Level:** Medium
- **Recent (20 days) Relative Divergence Change:** -1.60 (worsening)
- **7-day Rank Change:** 46 (rank up)
- **7-day Dynamic Expected Return Change:** -58.80 (worsening)
- **Expected Return:** -356.70%

### Recent News & Significant Events
- [2026-01-04] Don't Buy UnitedHealth Group Stock Before Jan. 27 - The Motley Fool
- [2026-01-04] Don't Buy UnitedHealth Group Stock Before Jan. 27 - Yahoo Finance
- [2026-01-21] UnitedHealth rebating profits from ACA plans to customers (UNH:NYSE) - Seeking Alpha
- [2026-01-21] UnitedHealth Group (NYSE:UNH) Stock Price Up 2.3% - Here's Why - MarketBeat
- [2026-01-15] UNH Stock vs. CVS - Forbes
- [2026-01-20] UnitedHealth Group Stock (UNH) Opinions on Senate Medicare Report - Quiver Quantitative

### Analyst Opinions
- **Key:** Buy
- **Mean (1=StrongBuy~5=Sell):** 1.93 (~Buy)
- **Opinions:** 26
- **Target Price (avg/high/low):** 393.85 / 444.00 / 280.00

### Recent Earnings Analysis
| Date | EPS | Revenue |
|-----|-----|---------|
| 2025-10-28 | 2.59 | $113.16B |
| 2025-08-11 | 3.76 | $111.62B |
| 2025-05-07 | 6.9 | $109.58B |
| 2024-11-04 | 6.56 | $100.82B |
| 2025-10-28 | 6.56 | $100.82B |

### Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $113.16B | 18.24% |
| 2025-06-30 | $111.62B | 17.93% |
| 2025-03-31 | $109.58B | 21.70% |
| 2024-12-31 | $100.81B | 21.14% |
| 2024-09-30 | $100.82B | 22.84% |

### Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $95.79B | 2.45% |
| 2025-06-30 | $94.72B | 3.60% |
| 2025-03-31 | $95.04B | 6.62% |
| 2024-12-31 | $92.66B | 5.98% |
| 2024-09-30 | $94.53B | 6.41% |

### Comprehensive Analysis (Summary)
UnitedHealth Group has experienced a high degree of divergence in its return rate compared to the S&P 500. Recent stock price fluctuations indicate a slight rebound, but the 60-day SMA suggests a downward trend. The RSI and PPO analysis show a medium risk investment, with worsening trends in relative divergence and expected return. Analyst opinions suggest a buy rating, but earnings analysis shows decreasing revenue and profit margin. The company has significant equity and ROE variations across different quarters.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.